(CercleFinance.com) – Alpha MOS announced yesterday evening that it has concluded, according to schedule, the second clinical study relating to its non-invasive glucose monitoring device using breath analysis.
According to the company, the study – which was launched at the end of 2021 by the Toulouse University Hospital and which involved 130 patients with type 2 diabetes – met the objectives set.
In a press release, Alpha Mos indicates that it has made it possible to establish the success of the functional test of the system, but also to confirm the interest of patients for this new device, developed by its medtech subsidiary BOYDSense.
‘This information is one more step towards the design of a complete device for monitoring glucose by breath analysis and its marketing,’ reacted this morning the analysts from Euroland.
The research department maintains its buy recommendation on the stock, with an unchanged target price of 30 euros.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
